Menu Search
Equities

Tsumura & Co

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TSMRF:PKL

Tsumura & Co

Actions
  • Price (USD)23.20
  • Today's Change0.00 / 0.00%
  • Shares traded400.00
  • 1 Year change--
  • Beta0.3640
Data delayed at least 15 minutes, as of Aug 25 2025 18:01 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Tsumura & Co is a Japan-based company mainly engaged in manufacturing and sales of prescription drugs and over-the-counter drugs. The Company operates the Pharmaceuticals segment. In Japan, the Company conducts the manufacturing, sales, transportation and storage of prescription drugs and over-the-counter drugs, and cultivation, procurement, selection, processing and storage of raw medicinal herbs. In China, the Company is engaged in regional management, business management, production and sales of herbal extract powders, cultivation, procurement, selection, processing and storage of herbal ingredients, and sales of pharmaceuticals and food products. In Laos, the Company is engaged in cultivation, procurement, selection, processing and storage of herbal ingredients. In the United States, the Company is engaged in pharmaceutical development business.

  • Revenue in JPY (TTM)189.50bn
  • Net income in JPY29.01bn
  • Incorporated1936
  • Employees4.27k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		4540:TYO since
announced		Transaction
value
YOMEISHU SEIZO CO LTDRumoured03 Feb 202603 Feb 2026Rumoured-0.34%--
Data delayed at least 15 minutes, as of Feb 16 2026 06:30 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.